BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, July 6, 2025
Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
Substance use and poisoning RSS Feed RSS

Substance Use & Poisoning

Dual sigma receptor and DAT antagonists reported in University of Florida patent

Oct. 23, 2023
Research at the University of Florida has led to the identification of compounds acting as dual dopamine transporter (DAT) and sigma receptor (sigma nonopioid intracellular receptor 1 [σ1, SIGMAR1] and sigma intracellular receptor 2 [σ2, TMEM97]) antagonists reported to be useful for the treatment of methamphetamine dependence and cocaine dependency.
Read More
Illustration of syringe inside birdcage shaped like a human head
Substance Use & Poisoning

IVL-3004, a novel naltrexone-loaded microsphere formulation with improved PK and safety profile

Oct. 20, 2023
Researchers from Inventage Lab Inc. have presented preclinical data for its naltrexone-loaded microspheres, named IVL-3004, developed as long-acting injectable using the proprietary IVL-Drugfluidic technology platform.
Read More
Concept art for "unlocking the secrets of the mind"
Substance Use & Poisoning

Novel human in vitro model of preBötC-like neurons for the study of opioid overdose and recovery

Sep. 15, 2023
The preBötzinger complex (preBötC) appears to play a relevant role in opiate-induced respiratory depression, as suggested by studies in animal models. However, limited research concerning preBötC physiology in humans has been conducted, and no human in vitro models of the preBötC exist.
Read More
Silhouette of head, brain
Neurology/Psychiatric

Phoenix Pharmalabs’ PPL-138 reduces alcohol use and symptoms of PTSD in rat model

Sep. 15, 2023
Phoenix Pharmalabs Inc. has reported findings from in vivo studies that demonstrated that the company’s lead compound, PPL-138, reduced symptoms of post-traumatic stress disorder (PTSD) and decreased alcohol consumption in a rat model of PTSD/alcohol use disorder (AUD). The studies were conducted at the University of Oklahoma Health Sciences Center and Florida Atlantic University under a grant from the U.S. Department of Defense.
Read More
3D drawing of molecular structure of ricin
Substance Use & Poisoning

Antoxa and Swiftpharma collaborate to advance plant-made antibody against ricin exposure

Sep. 6, 2023
Antoxa Corp. and Swiftpharma BV have signed an exclusive collaboration agreement to support the development and commercialization of a plant-made monoclonal antibody against ricin exposure.
Read More
Beaker and radioactive icons
Substance Use & Poisoning

NIAID grant supports Ceramedix's development of anti-ceramide antibody for GI ARS

Aug. 25, 2023
Ceramedix Holding LLC has been awarded a phase IIB Small Business Innovation Research (SBIR) grant valued at approximately US$3 million by the National Institute of Allergy and Infectious Diseases (NIAID) to support the evaluation of the non-clinical pharmacology of its lead drug candidate. The anti-ceramide antibody is in development through the National Institutes of Health (NIH) as a potential therapeutic to mitigate and/or treat illness due to radiation exposure.
Read More
3D illustration of a nerve cell
Neurology/Psychiatric

Novel dual opioid analgesic with improved safety profile disclosed

Aug. 25, 2023
Mu opioid receptors (MOR) agonists exert strong anti-nociceptive activity but their ability to cause tolerance and physical dependence are serious issues of concern and limit their use. The activation of another branch of opioid receptors discovered lately, the opioid-related nociceptin receptor 1 (OPRL1) has recently shown the ability to enhance MOR agonist-induced analgesia while limiting tolerance and side effects.
Read More
Illustration highlighting the brain's reward circuit.
Substance Use & Poisoning

First-in-class RXFP3 negative allosteric modulator RLX-33 prevents alcohol relapse in rats

Aug. 24, 2023
New treatment options are needed for the prevention of relapse to alcohol use, the major problem in the treatment of alcohol dependence in humans. The neuropeptide relaxin-3/RXFP3 plays a relevant role in the motivation for the reward process and is considered a possible therapeutic target in addictive behaviors.
Read More
Neurology/Psychiatric

Gene therapy shows early promise for treating severe alcohol addiction

Aug. 18, 2023
By Helen Albert
Research in rhesus monkeys has shown a gene therapy that enhanced activity in dopamine producing neurons in the brain was effective at stopping excessive alcohol consumption in previously addicted animals.
Read More
Substance Use & Poisoning

AAV2-hGDNF revealed as a novel strategy for substance use disorders

Aug. 17, 2023
Alcohol use disorder (AUD) refers to a medical condition, considered a brain disorder, where individuals are unable to stop drinking alcohol...
Read More
Previous 1 2 3 4 5 6 7 8 9 … 118 119 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing